Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 120.00K |
Gross Profit | 0.00 | -374.00K | -373.00K | -195.00K | -63.00K |
EBITDA | -35.39M | -116.16M | -87.59M | -36.66M | -23.03M |
Net Income | -35.32M | -40.33M | -87.50M | -34.51M | -22.81M |
Balance Sheet | |||||
Total Assets | 177.41M | 89.07M | 92.79M | 170.55M | 197.19M |
Cash, Cash Equivalents and Short-Term Investments | 140.18M | 51.10M | 56.41M | 84.83M | 114.19M |
Total Debt | 954.00K | 383.00K | 746.00K | 769.00K | 144.00K |
Total Liabilities | 59.27M | 81.86M | 8.61M | 6.55M | 6.59M |
Stockholders Equity | 118.14M | 7.21M | 84.18M | 164.00M | 190.60M |
Cash Flow | |||||
Free Cash Flow | -47.27M | -39.53M | -28.42M | -28.91M | -15.21M |
Operating Cash Flow | -47.27M | -39.53M | -28.42M | -28.91M | -15.21M |
Investing Cash Flow | -70.31M | -45.29M | 0.00 | 0.00 | 11.04M |
Financing Cash Flow | 133.52M | 33.02M | 0.00 | -449.00K | 109.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $231.05M | ― | -140.82% | ― | -48.37% | -44.70% | |
57 Neutral | $230.37M | ― | -414.88% | ― | -65.96% | 40.80% | |
52 Neutral | $7.46B | -0.04 | -63.82% | 2.49% | 16.43% | <0.01% | |
47 Neutral | $241.27M | ― | -22.59% | ― | ― | 26.63% | |
38 Underperform | $254.54M | ― | -66.13% | ― | ― | 43.21% | |
35 Underperform | $222.16M | ― | -83.30% | ― | ― | 69.29% | |
33 Underperform | $206.12M | ― | -124.74% | ― | ― | -20.39% |
Eledon Pharmaceuticals announced an amendment to the employment agreement of its CEO, David-Alexandre Gros, adjusting the market value cap for his performance bonus. The CEO’s bonus structure has been altered, allowing for a maximum bonus of $15 million if the company’s market value reaches $1.5 billion, with linear interpolation determining payouts between set thresholds.